前列地尔治疗小儿高原性心脏病合并心功能不全的临床疗效观察  

Clinical Evaluation of Lipo-prostagland E_1 in the Treatment of Children High Altitude Heart Disease with Heart Failure

作　　者：夏清[1] 王崇忠 张晓庆[1] 胥亚福 李毅[1] 刘志红[1] 

机构地区：[1]阿坝州人民医院儿科,四川马尔康624000

出　　处：《四川医学》2015年第8期1081-1083,共3页Sichuan Medical Journal

摘　　要：目的观察前列地尔治疗小儿高原性心脏病肺动脉高压的临床疗效。方法将64例小儿高原性心脏病患儿分为对照组30例和治疗组34例,对照组30例为常规治疗,治疗组34例加用前列地尔,观察两组临床疗效、右室流出道内径、右心室内径、右肺动脉内径及肺动脉收缩压(PASP)、N末端脑钠肽前体(NT-pro BNP)的变化。结果治疗组较对照组疗效显现更快,临床疗效、右室流出道内径、右心室内径、右肺动脉内径及PASP、NT-pro BNP明显改善,差异有临床统计意义(P<0.05),治疗组有效率90.1%,对照组有效率80%,差异有临床统计意义(P<0.05)。结论前列地尔治疗小儿的高原心脏病合并心功能不全,能显著降低肺动脉压力,改善心功能,为安全有效的治疗方法。Objective To study the effect of the lipo-prostagland E1 in the treatment of children high altitude heart disease with heart failure. MethodS 64 children with altitude heart disease with heart failure were randomly divided into a treatment group 34 and a control group 30. The control group received normal therapy while the treatment group were administered with the lipo-prostagland E1 The clinical effect before and after treatment, the change in artery blood gas analysis and pulmonary arterial systolic pressure, NET-proBNP and diameter of RvOT, Rv and RPA were recorded. Results The appearance of the curative effect of the treatment group was faster than that of the control group; there was a significant improvement in artery blood gas analy- sis, pulmonary arterial systolic pressure, NET-proBNP and the diameter of RVOT, RV, RPA;The effective rate of the treatment group and control group were 91.1% and 80%, respectively, and there were significant difference between the two groups（ P 〈 0. 05）. Conclusion lipo-prostagland E1 in the treatment of children high altitude heart disease with heart failure could reduce PASP significantly, improve the heart function and could be used as an effective and safe therapy.

关 键 词：小儿高原性心脏病 心功能不全 前列地尔 低氧性肺动脉高压 

分 类 号：R725.4[医药卫生—儿科]